BioMedSA’s Board of Directors approved 2 new memberships in April, 2022: BellaMia Technologies, and NanoHarmonics.
NanoHarmonics is creating diagnostic biomarker tests using their patented Quantum Dot technology, Abacus™. They have conducted clinical trials on their first applications: sepsis, COVID-19 antigens and COVID-19 neutralizing antibodies. They have recently partnered with Avagen Pharma in order to work towards their goal of improving pharmaceutical and diagnostics within the healthcare industry.